<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051098</url>
  </required_header>
  <id_info>
    <org_study_id>3374-2016</org_study_id>
    <secondary_id>848223</secondary_id>
    <secondary_id>05.220</secondary_id>
    <nct_id>NCT05051098</nct_id>
  </id_info>
  <brief_title>A Non-interventional Registry for Patients With Hepatitis B Virus Infection</brief_title>
  <official_title>The European HBV Registry: A Joint Initiative of TherVacB and DZIF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Center for Infection Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Liver Foundation (DLS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical&#xD;
      partners has gathered to establish a registry for patients with hepatitis B mono- and&#xD;
      co-infections. The partners will build up a European-wide registry to be able to stratify&#xD;
      patients for upcoming clinical trials.&#xD;
&#xD;
      Extensive analyses of virus and host-specific parameters are to be carried out from these&#xD;
      patients. The knowledge gained thereby should contribute to a better understanding of the HBV&#xD;
      control and enable patient stratification with regard to immunomodulatory therapies.&#xD;
&#xD;
      Furthermore, hepatitis B patients are to be identified who are willing to participate in&#xD;
      future studies to investigate immunotherapies to cure HBV infections (e.g. therapeutic&#xD;
      vaccines).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of patients with change HBsAg levels</measure>
    <time_frame>5 years</time_frame>
    <description>Regular assessment of quantitative HBsAg levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with seroconversion to anti-HBs</measure>
    <time_frame>5 years</time_frame>
    <description>Measurement of quantitative HBsAg and anti-HBs levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of IL6, IP-10, IFNg and IL1beta and correlation with HBsAg and ALT levels</measure>
    <time_frame>5 years</time_frame>
    <description>Cytokine and Chemokine quantification in patients for subsequent correlation with viral parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hepatitis B related increased or decreased quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Regular assessment of QOL by SF36 questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hepatitis B related HCC (hepatocellular carcinoma)</measure>
    <time_frame>5 years</time_frame>
    <description>Regular assessment of HCC status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hepatitis B related liver cirrhosis</measure>
    <time_frame>5 years</time_frame>
    <description>Regular assessment of liver status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hepatitis B related death</measure>
    <time_frame>5 years</time_frame>
    <description>Regular quantification of lost-to-follow-up reasons.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Hepatitis B Virus Infection</condition>
  <arm_group>
    <arm_group_label>TherVacB Subgroup</arm_group_label>
    <description>No interventions. The participating study centers of the EU funded project &quot;TherVacB&quot; recruit patients with stricter inclusion- and exclusion criteria, hence forming a sub-cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>TherVacB Subgroup</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients seen in day clinic or outpatient clinic at the participating study centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatitis B Virus Infection&#xD;
&#xD;
        TherVacB sub-cohort:&#xD;
&#xD;
          -  confirmed chronic hepatitis B virus infection: HBsAg positive for at least 1 year&#xD;
             prior inclusion&#xD;
&#xD;
          -  HBeAg status documented for at least 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        TherVacB sub-cohort:&#xD;
&#xD;
          -  age &gt;70 years&#xD;
&#xD;
          -  co-infection with HIV, HCV (RNA positive),&#xD;
&#xD;
          -  clinically relevant concomitant liver diseases (ALD, NASH, Haemochromatosis,&#xD;
             Autoimmune hepatitis, AT1, Wilson's disease, primary biliary cirrhosis etc.)&#xD;
&#xD;
          -  significant comorbidities (e.g. malignancies)&#xD;
&#xD;
          -  immunosuppressive treatment (&gt; 40 mg Cortisol- equivalent)&#xD;
&#xD;
          -  liver cirrhosis (judged clinically or based on ultrasound/transient elastography)&#xD;
&#xD;
          -  History of hepatocellular carcinoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Markus Cornberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Forns</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacio Clinic per a la Recerca Biomedica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petra Dörge</last_name>
    <phone>+49511532</phone>
    <phone_ext>6057</phone_ext>
    <email>doerge.petra@mh-hannover.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Dörge</last_name>
      <phone>+49511532</phone>
      <phone_ext>6057</phone_ext>
      <email>doerge.petra@mh-hannover.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided which and where data will be shared. Depends on regulatory requirements of EU and German Federal Ministry of Education and Research</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

